Login to Your Account

Subanalysis in Asian patients yields solid data for Pfizer's Ibrance

By Carmen Ho
Staff Writer

Friday, December 23, 2016

HONG KONG – Pfizer Inc. said its FDA breakthrough-designated breast cancer drug, Ibrance, could have a significant impact in Asia, based on a subanalysis in Asian women from a phase III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription